Use of oseltamivir in children.
Blake Jamieson, Rini Jain, Bruce Carleton, Ran D. Goldman
Abstract
Blake Jamieson, Rini Jain, Bruce Carleton, Ran D. Goldman
Abstract
QUESTION: Because of the recent outbreak of pandemic H1N1 2009, I am anticipating a large number of children with influenza-like symptoms or children diagnosed with influenza. Is oseltamivir effective and safe when used for children? ANSWER: Oseltamivir is effective for prevention of complications associated with influenza A (including H1N1) in children. Oseltamivir also reduces the duration of influenza by a median of 36 hours, with nausea and vomiting as the primary reported adverse effects. The World Health Organization recommends oseltamivir as first-line treatment for H1N1, with the use of zanamivir only for suspected or confirmed oseltamivir resistance. Recently, in preparation for the influenza A (H1N1) 2009 pandemic, Health Canada published an interim order permitting the expanded use of oseltamivir for treatment or prophylaxis for children younger than 1 year of age.
OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
QUESTION: Because of the recent outbreak of pandemic H1N1 2009, I am anticipating a large number of children with influenza-like symptoms or children diagnosed with influenza. Is oseltamivir effective and safe when used for children? ANSWER: Oseltamivir is effective for prevention of complications associated with influenza A (including H1N1) in children. Oseltamivir also reduces the duration of influenza by a median of 36 hours, with nausea and vomiting as the primary reported adverse effects. The World Health Organization recommends oseltamivir as first-line treatment for H1N1, with the use of zanamivir only for suspected or confirmed oseltamivir resistance. Recently, in preparation for the influenza A (H1N1) 2009 pandemic, Health Canada published an interim order permitting the expanded use of oseltamivir for treatment or prophylaxis for children younger than 1 year of age.
Key concepts: Oseltamivir, Zanamivir, Interim, Medicine, Pandemic, Vomiting, Neuraminidase inhibitor, Adverse effect